Additional file 5: Figure S2.
European League Against Rheumatism (EULAR) responses of at least ‘moderate’ and ‘good’ for those patients with prior use of TNF antagonists and TNF antagonist-naive patients. Data are shown as observed values for all evaluable patients at each time point during long-term treatment with adalimumab (ADA). LO, last observation.
Format: PDF Size: 29KB Download file
This file can be viewed with: Adobe Acrobat Reader
Burmester et al. Arthritis Research & Therapy 2014 16:R24 doi:10.1186/ar4452